Fused cyclic modulators of nuclear hormone receptor function

Abstract

The invention pertains to fused cyclic compounds having the formula,wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CRRor NR, and M' is a bond or NR, with the proviso that at least one of M or M′ must be a bond; E is C═Z, CRCR, SO, P═OR, or P═OOR; Zis O, S, NH, or NR; Zis O, S, NH, or NR; Ais CRor N; Ais CRor N; Y is J—J′—J″ where J is (CRR)n and n=0-3, J′ is a bond or O, S, S═O, SO, NH, NR, C═O, OC═O, NRC═O, CRR, C═CRR, RP═O, OPOOR, OPO, OSO, C═N, NHNH, NHNR, NRNH, N═N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J″ is (CRR)n and n=0-3; W is CRR—CRR, CR═CR, CRR—C═O, NR—CRR, N═CR, N═N, NR—NR′, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; and O, R, R, R, R, R, R, R, R, and Rare as defined in the specification, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to pharmaceutical compositions containing such compounds.